Activity of ceftazidime/avibactam against problem Enterobacteriaceae and Pseudomonas aeruginosa in the UK, 2015-16

Journal of Antimicrobial Chemotherapy

Volumn 73, Issue 3, 2018, Pages 648-657

  Livermore, David M ^a,b   Meunier, Danièle ^a   Hopkins, Katie L ^a   Doumith, Michel ^a   Hill, Robert ^a   Pike, Rachel ^a   Staves, Peter ^a   Woodford, Neil ^a  

^a PUBLIC HEALTH ENGLAND   (United Kingdom)

^b UNIVERSITY OF EAST ANGLIA   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

AMIKACIN; AMOXICILLIN PLUS CLAVULANIC ACID; AVIBACTAM; AVIBACTAM PLUS CEFTAZIDIME; AZTREONAM; BACTERIAL ENZYME; BETA LACTAMASE AMPC; CARBAPENEMASE; CARBENICILLIN; CEFEPIME; CEFOTAXIME; CEFOXITIN; CEFTAZIDIME; CEFTOLOZANE; CIPROFLOXACIN; ERTAPENEM; EXTENDED SPECTRUM BETA LACTAMASE; GENTAMICIN; IMIPENEM; MEROPENEM; PIPERACILLIN PLUS TAZOBACTAM; TEMOCILLIN; ANTIINFECTIVE AGENT; AVIBACTAM, CEFTAZIDIME DRUG COMBINATION; AZABICYCLO DERIVATIVE; BACTERIAL PROTEIN; BETA LACTAMASE; BETA LACTAMASE INHIBITOR;

ANTIBACTERIAL ACTIVITY; ANTIBIOTIC RESISTANCE; ARTICLE; BACTERIAL STRAIN; BACTERIUM ISOLATE; CITROBACTER; DRUG POTENTIATION; ENTEROBACTER CLOACAE; ENTEROBACTERIACEAE; ESCHERICHIA COLI; HAFNIA ALVEI; KLEBSIELLA OXYTOCA; KLEBSIELLA PNEUMONIAE; MINIMUM INHIBITORY CONCENTRATION; MORGANELLA MORGANII; NONHUMAN; PROVIDENCIA; PSEUDOMONAS AERUGINOSA; SERRATIA; UNITED KINGDOM; BIOSYNTHESIS; DRUG COMBINATION; DRUG EFFECT; ENTEROBACTERIACEAE INFECTION; ENZYMOLOGY; GENETICS; HUMAN; MICROBIAL SENSITIVITY TEST; MULTIDRUG RESISTANCE; POLYMERASE CHAIN REACTION; PSEUDOMONAS INFECTION;

ANTI-BACTERIAL AGENTS; AZABICYCLO COMPOUNDS; BACTERIAL PROTEINS; BETA-LACTAMASE INHIBITORS; BETA-LACTAMASES; CEFTAZIDIME; DRUG COMBINATIONS; DRUG RESISTANCE, MULTIPLE, BACTERIAL; ENTEROBACTERIACEAE; ENTEROBACTERIACEAE INFECTIONS; HUMANS; KLEBSIELLA PNEUMONIAE; MICROBIAL SENSITIVITY TESTS; POLYMERASE CHAIN REACTION; PSEUDOMONAS AERUGINOSA; PSEUDOMONAS INFECTIONS; UNITED KINGDOM;

EID: 85043332988     PISSN: 03057453     EISSN: 14602091     Source Type: Journal    
DOI: 10.1093/jac/dkx438     Document Type: Article

References (32)

1. Zasowski EJ, Rybak JM, Rybak MJ. The β-lactams strike back: ceftazidimeavibactam. Pharmacotherapy 2015; 35: 755-70.
2. Shlaes DM. New β-lactam-β-lactamase inhibitor combinations in clinical development. AnnNYAcadSci 2013; 1277: 105-14.
3. Ehmann DE, Jahic H, Ross PL et al. Kinetics of avibactam inhibition against Class A, C, and D β-lactamases. J Biol Chem 2013; 288: 27960-71.
4. Stojanoski V, Chow DC, Fryszczyn B et al. Structural basis for different substrate profiles of two closely related Class D β-lactamases and their inhibition by halogens. Biochemistry 2015; 54: 3370-80.
5. Livermore DM, Mushtaq S, Warner M et al. Activities of NXL104 combinations with ceftazidime and aztreonam against carbapenemase-producing Enterobacteriaceae. Antimicrob Agents Chemother 2011; 55: 390-4.
6. Mushtaq S, Warner M, Livermore DM. In vitro activity of ceftazidime!NXL104 against Pseudomonas aeruginosa and other non-fermenters. J Antimicrob Chemother 2010; 65: 2376-81.
7. Livermore DM, Mushtaq S, Meunier D et al. Activity of ceftolozane/tazobactam against surveillance and 'problem' Enterobacteriaceae, Pseudomonas aeruginosa and non-fermenters from the British Isles. J Antimicrob Chemother 2017; 72: 2278-89.
8. A guide to sensitivity testing. Report of the Working Party on Antibiotic Sensitivity Testing of the British Society for Antimicrobial Chemotherapy JAntimicrobChemother 1991; 27 Suppl D: 1-50.
9. Ellington MJ, Findlay J, Hopkins KL et al. Multicentre evaluation of a realtime PCR assay to detect genes encoding clinically relevant carbapenemases in cultured bacteria. Int J Antimicrob Agents 2016; 47: 151-4.
10. Ellington MJ, Kistler J, Livermore DM et al. Multiplex PCR for rapid detection of genes encoding acquired metallo-β-lactamases. J Antimicrob Chemother 2007; 59: 321-2.
11. Meunier D, Findlay J, Doumith M et al. FRI-2 carbapenemase-producing Enterobacter cloacae complex in the UK. J Antimicrob Chemother 2017; 72: 2478-82.
12. Doumith M, Godbole D, Ashton P et al. Detection of the plasmidmediated mcr-1 gene conferring colistin resistance in human and food isolates of Salmonella enterica and Escherichia coli in England and Wales. J Antimicrob Chemother 2016; 71: 2300-5.
13. HMMER. Eddlylab. http://hmmer.org.
14. European Molecular Biology Laboratory. Pfam Database. http://pfam.xfam.org.
15. Winstanley T, Courvalin P. Expert systems in clinical microbiology. Clin Microbiol Rev 2011; 24: 515-56.
16. Livermore DM, Winstanley TG, Shannon KP. Interpretative reading: recognizing the unusual and inferring resistancemechanisms from resistance phenotypes J Antimicrob Chemother 2001; 48 Suppl 1: 87-102.
17. British Society for Antimicrobial Chemotherapy. Resistance Surveillance Programmes. http://www.bsacsurv.org.
18. PHE English Surveillance Programme for Antimicrobial Utilisation and Resistance (ESPAUR). https://www.gov.uk/government/uploads/system/uploads/attachment_data/file/575626/ESPAUR_Report_2016.pdf.
19. Doumith M, Ellington MJ, Livermore DM et al. Molecular mechanisms disrupting porin expression in ertapenem-resistant Klebsiella and Enterobacter spp. clinical isolates from the UK. J Antimicrob Chemother 2009; 63: 659-67.
20. Livermore DM, Warner M, Jamrozy D et al. In vitro selection of ceftazidime-avibactam resistance in Enterobacteriaceae with KPC-3 carbapenemase. Antimicrob Agents Chemother 2015; 59: 5324-30.
21. Shields RK, Potoski BA, Haidar G et al. Clinical outcomes, drug toxicity, and emergence of ceftazidime-avibactam resistance among patients treated for carbapenem-resistant Enterobacteriaceae infections. Clin Infect Dis 2016; 63: 1615-8.
22. Turton JF, Perry C, Elgohari S et al. PCR characterization and typing of Klebsiella pneumoniae using capsular type-specific, variable number tandem repeat and virulence gene targets. JMedMicrobiol 2010; 59: 541-7.
23. Findlay J, Hopkins KL, Loy R et al. OXA-48-like carbapenemases in the UK:an analysis of isolates and cases from 2007 to 2014. J Antimicrob Chemother 2017; 72: 1340-9.
24. Logan LK, Weinstein RA. The epidemiology of carbapenem-resistant Enterobacteriaceae: the impact and evolution of a globalmenace J Infect Dis 2017; 215 Suppl 1: S28-36.
25. Grundmann H, Glasner C, Albiger B et al.; European Survey of Carbapenemase-Producing Enterobacteriaceae (EuSCAPE) Working Group. Occurrence of carbapenemase-producing Klebsiella pneumoniae and Escherichia coli in the European survey of carbapenemase-producing Enterobacteriaceae (EuSCAPE): a prospective, multinational study. Lancet Infect Dis 2017; 17: 153-63.
26. Winkler ML, Papp-Wallace KM, Bonomo RA. Activity of ceftazidime/avibactam against isogenic strains of Escherichia coli containing KPC and SHV β-lactamaseswith single amino acid substitutions in the X-loop. J Antimicrob Chemother 2015; 70: 2279-86.
27. Both A, Büttner H, Huang J et al. Emergence of ceftazidime/avibactam non-susceptibility in an MDR Klebsiella pneumoniae isolate. J Antimicrob Chemother 2017; 72: 2483-8.
28. Skurnik D, Lasocki S, Bremont S et al. Development of ertapenem resistance in a patient with mediastinitis caused by Klebsiella pneumoniae producing an extended-spectrum β-lactamase. J Med Microbiol 2010; 59: 115-9.
29. Findlay J, Hamouda A, Dancer SJ et al. Rapid acquisition of decreased carbapenem susceptibility in a strain of Klebsiella pneumoniae arising during meropenem therapy. Clin Microbiol Infect 2012; 18: 140-6.
30. Babini GS, Livermore DM. Are SHV β-lactamases universal in Klebsiella pneumoniae? Antimicrob Agents Chemother 2000; 44: 2230.
31. Petit A, Ben Yaghlane-Bouslama H, Sofer L et al. Does high level production of SHV-type penicillinase confer resistance to ceftazidime in Enterobacteriaceae? FEMS Microbiol Lett 1992; 71: 89-94.
32. Livermore DM, Mushtaq S, Warner M et al. In vitro activity of cefepime/ zidebactam (WCK 5222) against Gram-negative bacteria. J Antimicrob Chemother 2017; 72: 1373-85.